MedTrace Logo

LAEH Formulation Nasal Spray to Reduce Viral Load

NCT05768113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-03-14

No results posted yet for this study

Summary

The Covixyl-V LAEH Nasal Spray's safety and efficay is clinically tested for use in subjects with COVID-19 infection.

A randomized, double-blind, multi-center study is conducted to evaluate the efficacy and safety of ethyl lauroyl arginate hydrochloride (LAEH) formulation versus a matching placebo formulation administered as a nasal spray to reduce viral load from nasal area of subjects with coronavirus disease 2019 (COVID-19).

Conditions

  • Coronavirus Disease

Sponsors & Collaborators

  • Salvacion USA Inc.

    lead INDUSTRY

Principal Investigators

  • Jorge Amaya P Amaya, MD · 8485 Bird Road, Suite 303, Miami FL 33155

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-29
Primary Completion
2021-10-04
Completion
2022-01-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05768113 on ClinicalTrials.gov